



Company announcement

Mr Handojo (Jet) Soedirdja resigns as a Non-Executive Director

Melbourne, Australia. Tuesday 31 January 2012

The board of Avexa Limited [ASX:AVX] today announced that Mr Handojo (Jet) Soedirdja has resigned as a Non-Executive Director due to personal time constraints arising from his other professional commitments.

Mr Iain Kirkwood, Chairman of Avexa Limited, thanked Mr Soedirdja for his work with the company since his appointment to the board on July 2010, especially in his role as Deputy Chairman, and also for his valuable input into recent strategic investments made by Avexa.

“Jet has been a valuable part of the Avexa team, and has contributed strongly in steering Avexa through some difficult times. I wish him well for the future,” Mr Kirkwood said.

About Avexa Limited

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa’s key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

For more information:

Mr Iain Kirkwood
Chairman
Ph: +61 3 9208 4300

Dr Jonathan Coates
Avexa Interim CEO
Ph: +61 3 9208 4300

Richard Allen
Oxygen Financial Public Relations
Ph: + 61 3 9915 6341